Sarepta Therapeutics (SRPT) Price & Analysis

Compare

3,968 Followers

SRPT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$10.42 - $138.81

Previous CloseN/A

Volume185.86K

Average Volume (3M)15.64M

Market Cap

$1.77B

Enterprise Value$2.38B

Total Cash (Recent Filing)$800.14M

Total Debt (Recent Filing)$1.35B

Price to Earnings (P/E)19.6

Beta0.75

Next Earnings

Oct 29, 2025

EPS Estimate

-0.63

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.89

Shares Outstanding97,713,440

10 Day Avg. Volume10,067,485

30 Day Avg. Volume15,638,477

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.34

Enterprise Value/Revenue0.96

Enterprise Value/Gross Profit1.21

Enterprise Value/Ebitda54.06

Forecast

1Y Price Target

$24.33

Price Target Upside31.80% Upside

Rating ConsensusHold

Number of Analyst Covering29

Bulls Say, Bears Say

Bulls Say

FDA RecommendationThe FDA recommended Elevidys shipments in ambulatory patients resume, which supports the company's sales efforts.

Financial FlexibilityExtending the maturity of a large portion of its near term outstanding debt enhances the company's financial flexibility, allowing Sarepta to continue funding its pipeline while focusing on sales of Elevidys and the PMO franchise.

Milestone AchievementThe company announced fulfilling the $100M milestone triggered by Arrowhead reaching the first enrollment target in the Ph1/2 study of SRP-1003.

Bears Say

Creditor SkepticismCreditor split and loss of covenant protection flag skepticism over Sarepta's survival to 2030.

Elevidys Launch UncertaintyThe trajectory of the Elevidys launch remains unclear, with expectations of slower uptake despite positive feedback.

Exon Skipping Franchise RiskRevenues from the exon skipping franchise are at risk ahead of the post-marketing trial readouts in 2026.

Sarepta Therapeutics News

Sarepta put volume heavy and directionally bearish

Bearish flow noted in Sarepta (SRPT) with 4,670 puts trading, or 2x expected. Most active are Jan-26 20...

13h ago

SRPT

Sarepta down 10% on new adverse event report, says Deutsche Bank

Deutsche Bank attributes the 10% selloff in shares of Sarepta (SRPT) over the past week, at least in...

10d ago

SRPT

Elanco to replace Sarepta in S&P 400 at open on 9/2

17:25 EDT Elanco (ELAN) to replace Sarepta (SRPT) in S&P 400 at open on 9/2 Published first on...

10d ago

ELAN

SRPT

Sarepta to replace Brookline Bancorp in S&P 600 at open on 9/2

Berkshire Hills Bancorp (BHLB) is acquiring Brookline Bancorp (BRKL) in a deal expected to be completed soon, pending...

10d ago

BHLB

BRKL

Sarepta financing net negative for equity holders, says H.C. Wainwright

H.C. Wainwright reiterates a Sell rating on Sarepta (SRPT) with a $5 price target The company’s recent financing...

12d ago

SRPT

Walmart reports mixed Q2, Thoma Bravo to acquire Dayforce: Morning Buzz

The major averages were broadly lower near noon as investors await cues from the Jackson Hole symposium for...

16d ago

Sarepta debt refinancing eases liquidity concerns, says Barclays

Barclays says Sarepta’s (SRPT) debt refinancing was done on largely favorable terms and has minimized the company’s liquidity...

16d ago

SRPT

BofA trims Sarepta price target, says debt refinancing mitigates liquidity risk

BofA lowered the firm’s price target on Sarepta (SRPT) to $16 from $17 and keeps an Underperform rating...

16d ago

SRPT

Sarepta refinances $700M of convertible notes, extends maturities to 2030

Sarepta (SRPT) Therapeutics announced that it has entered into exchange agreements with a limited number of holders of...

16d ago

SRPT

Citi says FDA may take ‘more comprehensive look’ at Sarepta Elevidys adjustment

After Rocket Pharmaceuticals (RCKT) announced that the FDA has lifted the hold on RPA501 for Danon following alignment...

16d ago

RCKT

SRPT

Sarepta Therapeutics Restructures Amid ELEVIDYS Challenges

Sarepta Therapeutics Inc. (($SRPT)) has held its Q2 earnings call. Read on for the main highlights of the...

4d ago

SRPT

Sarepta Therapeutics Completes Convertible Notes Exchange

Sarepta Therapeutics ( ($SRPT) ) just unveiled an announcement. On August 20, 2025, Sarepta Therapeutics entered into exchange...

7d ago

SRPT

Sarepta, AST, CoreWeave, Enphase, Paramount: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($SRPT) ), ( ($ASTS) ), ( ($CRWV) ), ( ($ENPH)...

14d ago

ASTS

CRWV

Sarepta Therapeutics: Hold Rating Amid Debt Maturity Extension and Strategic Execution Focus

Morgan Stanley analyst Michael Ulz maintained a Hold rating on Sarepta Therapeutics yesterday and set a price target...

15d ago

SRPT

SRPT FAQ

What was Sarepta Therapeutics’s price range in the past 12 months?

Sarepta Therapeutics lowest stock price was $10.41 and its highest was $138.81 in the past 12 months.

What is Sarepta Therapeutics’s market cap?

Sarepta Therapeutics’s market cap is $1.77B.

When is Sarepta Therapeutics’s upcoming earnings report date?

Sarepta Therapeutics’s upcoming earnings report date is Oct 29, 2025 which is in 53 days.

How were Sarepta Therapeutics’s earnings last quarter?

Sarepta Therapeutics released its earnings results on Aug 06, 2025. The company reported $1.89 earnings per share for the quarter, beating the consensus estimate of $0.832 by $1.058.

Is Sarepta Therapeutics overvalued?

According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sarepta Therapeutics pay dividends?

Sarepta Therapeutics does not currently pay dividends.

What is Sarepta Therapeutics’s EPS estimate?

Sarepta Therapeutics’s EPS estimate is -0.63.

How many shares outstanding does Sarepta Therapeutics have?

Sarepta Therapeutics has 97,713,440 shares outstanding.

What happened to Sarepta Therapeutics’s price movement after its last earnings report?

Sarepta Therapeutics reported an EPS of $1.89 in its last earnings report, beating expectations of $0.832. Following the earnings report the stock price went up 10.455%.

Which hedge fund is a major shareholder of Sarepta Therapeutics?

Currently, no hedge funds are holding shares in SRPT

Sarepta Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-4.76%

Trailing 12-Months

Asset Growth

7.46%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sarepta Therapeutics

Sarepta Therapeutics (SRPT) is a biopharmaceutical company focused on developing innovative therapies for rare diseases, primarily targeting genetic disorders such as Duchenne muscular dystrophy (DMD). The company operates in the biotechnology sector and is known for its pioneering work in gene therapy and RNA-targeted medicines. Sarepta's lead product candidates include exon-skipping therapies and gene replacement therapies designed to address the underlying causes of DMD and other genetic conditions.

Sarepta Therapeutics (SRPT) Earnings & Revenues

Historic Earnings Reports

SRPT Company Deck

SRPT Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted significant strategic restructuring, cost-saving measures, and a focused pipeline to strengthen Sarepta's financial position and future growth. However, challenges such as workforce reduction, hesitancy in ELEVIDYS adoption, and suspension of nonambulatory ELEVIDYS shipments present significant hurdles.View all SRPT earnings summaries

SRPT Stock 12 Month Forecast

Average Price Target

$24.33

▲(31.80% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","37":"$37","70":"$70","103":"$103","136":"$136"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$80.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,37,70,103,136],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.16,22.916923076923077,27.673846153846156,32.43076923076923,37.18769230769231,41.94461538461539,46.70153846153846,51.458461538461535,56.21538461538462,60.972307692307695,65.72923076923077,70.48615384615385,75.24307692307693,{"y":80,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.16,18.634615384615383,19.10923076923077,19.583846153846153,20.05846153846154,20.533076923076923,21.007692307692306,21.482307692307693,21.956923076923076,22.43153846153846,22.906153846153845,23.38076923076923,23.855384615384615,{"y":24.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.16,17.147692307692306,16.135384615384616,15.123076923076923,14.11076923076923,13.098461538461539,12.086153846153845,11.073846153846153,10.061538461538461,9.04923076923077,8.036923076923078,7.024615384615384,6.012307692307692,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":135.78,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.33,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.29,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.95,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.59,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.72,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.78,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.74,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 79, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 93, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 26</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.16,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 74, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 24</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >